The Official Website of the Acid Maltase Deficiency Association

It is difficult to say what is impossible for the dreams of yesterday are the hopes of today and the reality of tomorrow. - Robert H. Goddard

August 2010 Pompe Program Update from Genzyme

Posted on: August 10, 2010

Genzyme would like to provide an update to the US Pompe community regarding the transition to commercial LumizymeTM (alglucosidase alfa) from the ATAP (Alglucosidase Alfa Temporary Access Program) in the United States. As a reminder, Lumizyme was approved by the US Food and Drug Administration (FDA) on May 24, 2010. Please visit for important safety information about Lumizyme including boxed warning for risk of anaphylaxis, severe allergic reactions, and immune-mediated reactions.

Download complete article

Disclaimer: The AMDA does not endorse any of the products, medications, treatments or information reported herein. The website and its contents is intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.

Address: AMDA PO Box 700248
San Antonio, Texas 78270 USA